Monopar Therapeutics Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Monopar Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $7.58K, a 60.79% increase year-over-year.
- Monopar Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $213.00.
- Monopar Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $4.71K, a 5508.33% increase year-over-year.
- Monopar Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $15.45K.
- Monopar Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $565.17K, a 672722.62% increase from fiscal 2024.
- Monopar Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $84.00.
- Monopar Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Monopar Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $169.00, a 99.03% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $7.58K 10-Q · filed 2026-08-12 | |
| 2025-12-31 | $565.17K 10-K · filed 2026-03-27 | |
| 2025-09-30 | $213.00 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $4.71K 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $15.45K 10-Q · filed 2026-08-12 | |
| 2024-12-31 | $84.00 10-K · filed 2026-03-27 | |
| 2024-06-30 | $84.00 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $0.00 10-K · filed 2024-03-28 | |
| 2023-09-30 | -$8.21K 10-Q · filed 2024-11-08 | |
| 2022-12-31 | $169.00 10-K · filed 2024-03-28 | |
| 2022-09-30 | $128.00 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $41.00 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $17.48K 10-K · filed 2023-03-23 | |
| 2021-03-31 | $17.48K 10-Q · filed 2021-11-12 | |
| 2019-12-31 | $110.00K 10-K · filed 2021-03-25 | |
| 2018-12-31 | $0.00 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |